Vecabrutinib (SNS-062), a reversible BTK inhibitor independent of the Cys481 residue, has in vitro cytotoxicity against BTK Cys481-mutated cell lines[179,180] and preliminary safety data in patients with CLL[173]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.